No Data
No Data
Zhejiang Shapuaisi Pharmaceutical (603168.SH): Received the "Pharmaceutical Supplement Application Approval Notice" for levofloxacin eye drops.
On May 9, Dongguan Gonghui reported that Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that the company received the "Notice of Approval for Supplementary Application of Pharmaceutical" (Notice Number: 2025B01972) issued by the National Medical Products Administration for levofloxacin eye drops. Indication: used for the treatment of blepharitis, meibomian gland inflammation, dacryocystitis, conjunctivitis, meibomian gland adenitis, keratitis, and as a sterilization treatment in ocular surgery.
Sharp Ace: Sharp Ace 2024 Annual Report Summary
SHAP-IS: SHAP-IS 2024 ANNUAL REPORT
Sharp Ace: Sharp Ace 2025 First Quarter Report
Sharp Ace 2024 Annual Report Summary
Sharp Ace 2025 First Quarter Report